Neil Everett Martin, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prostatic Neoplasms | 79 | 2024 | 11122 | 3.170 |
Why?
|
Prostatectomy | 24 | 2024 | 1824 | 1.310 |
Why?
|
Androgen Antagonists | 21 | 2024 | 1410 | 1.310 |
Why?
|
Testicular Neoplasms | 10 | 2024 | 799 | 1.160 |
Why?
|
Prostate-Specific Antigen | 19 | 2023 | 2469 | 1.120 |
Why?
|
Brachytherapy | 17 | 2021 | 1223 | 1.000 |
Why?
|
Radiosurgery | 6 | 2023 | 1342 | 0.930 |
Why?
|
Prostate | 12 | 2024 | 1773 | 0.820 |
Why?
|
Kallikreins | 3 | 2018 | 220 | 0.700 |
Why?
|
Health Status Indicators | 2 | 2015 | 970 | 0.670 |
Why?
|
Radiation Oncology | 4 | 2019 | 563 | 0.660 |
Why?
|
Hearing Loss | 6 | 2024 | 783 | 0.650 |
Why?
|
Tinnitus | 4 | 2023 | 196 | 0.540 |
Why?
|
Tosyl Compounds | 2 | 2014 | 115 | 0.510 |
Why?
|
Patient-Centered Care | 3 | 2016 | 1421 | 0.490 |
Why?
|
Quality Indicators, Health Care | 2 | 2015 | 1792 | 0.480 |
Why?
|
Gastrointestinal Diseases | 1 | 2023 | 1200 | 0.480 |
Why?
|
SEER Program | 18 | 2019 | 1450 | 0.460 |
Why?
|
Antineoplastic Agents, Hormonal | 5 | 2017 | 1520 | 0.460 |
Why?
|
Critical Pathways | 1 | 2017 | 474 | 0.450 |
Why?
|
RNA, Neoplasm | 2 | 2015 | 750 | 0.430 |
Why?
|
Medical Oncology | 2 | 2015 | 2321 | 0.420 |
Why?
|
Anilides | 2 | 2014 | 411 | 0.420 |
Why?
|
Flutamide | 1 | 2012 | 95 | 0.390 |
Why?
|
Health Status | 2 | 2015 | 4077 | 0.390 |
Why?
|
Radiotherapy | 5 | 2019 | 1498 | 0.370 |
Why?
|
Nitriles | 2 | 2014 | 971 | 0.360 |
Why?
|
Quality of Health Care | 3 | 2020 | 4331 | 0.330 |
Why?
|
Language | 1 | 2019 | 1543 | 0.330 |
Why?
|
Complementary Therapies | 1 | 2013 | 486 | 0.330 |
Why?
|
Male | 95 | 2024 | 360846 | 0.320 |
Why?
|
Cisplatin | 6 | 2024 | 1652 | 0.310 |
Why?
|
Adenocarcinoma | 6 | 2019 | 6345 | 0.310 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 3 | 2024 | 491 | 0.290 |
Why?
|
Neuralgia | 2 | 2024 | 615 | 0.290 |
Why?
|
Survivors | 3 | 2024 | 2371 | 0.290 |
Why?
|
Bone Neoplasms | 3 | 2017 | 2529 | 0.270 |
Why?
|
Health Personnel | 1 | 2020 | 3335 | 0.270 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 2013 | 1374 | 0.260 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2015 | 2865 | 0.260 |
Why?
|
Humans | 107 | 2024 | 761596 | 0.250 |
Why?
|
Neoplasm Staging | 17 | 2019 | 11120 | 0.250 |
Why?
|
Aged | 67 | 2024 | 169310 | 0.250 |
Why?
|
Patient Education as Topic | 1 | 2015 | 2319 | 0.240 |
Why?
|
Testosterone | 2 | 2014 | 2472 | 0.240 |
Why?
|
Cancer Care Facilities | 3 | 2017 | 422 | 0.240 |
Why?
|
Alkyl and Aryl Transferases | 1 | 2004 | 86 | 0.230 |
Why?
|
Healthcare Disparities | 6 | 2016 | 3358 | 0.220 |
Why?
|
Neoplasms, Second Primary | 4 | 2021 | 1052 | 0.220 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3086 | 0.200 |
Why?
|
Middle Aged | 58 | 2024 | 220921 | 0.200 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3206 | 0.200 |
Why?
|
Neoplasms | 7 | 2022 | 22173 | 0.200 |
Why?
|
Delivery of Health Care | 1 | 2020 | 5337 | 0.200 |
Why?
|
Travel | 2 | 2018 | 796 | 0.200 |
Why?
|
Tumor Burden | 3 | 2024 | 1892 | 0.190 |
Why?
|
Health Behavior | 1 | 2013 | 2644 | 0.190 |
Why?
|
Logistic Models | 12 | 2024 | 13255 | 0.190 |
Why?
|
Exercise | 2 | 2015 | 5890 | 0.190 |
Why?
|
Particle Accelerators | 1 | 2021 | 174 | 0.180 |
Why?
|
Salvage Therapy | 3 | 2017 | 1263 | 0.180 |
Why?
|
Proportional Hazards Models | 16 | 2020 | 12463 | 0.180 |
Why?
|
Early Detection of Cancer | 1 | 2015 | 3201 | 0.180 |
Why?
|
Marital Status | 4 | 2015 | 426 | 0.180 |
Why?
|
Watchful Waiting | 3 | 2019 | 491 | 0.170 |
Why?
|
Pandemics | 1 | 2020 | 8656 | 0.170 |
Why?
|
Palliative Care | 2 | 2017 | 3598 | 0.170 |
Why?
|
Databases, Factual | 10 | 2019 | 7968 | 0.160 |
Why?
|
Antineoplastic Agents | 6 | 2024 | 13642 | 0.160 |
Why?
|
PTEN Phosphohydrolase | 2 | 2015 | 1115 | 0.160 |
Why?
|
Anti-Anxiety Agents | 1 | 2021 | 397 | 0.150 |
Why?
|
Quality of Life | 4 | 2024 | 13367 | 0.150 |
Why?
|
Imidazoles | 1 | 2004 | 1180 | 0.150 |
Why?
|
Academic Medical Centers | 3 | 2017 | 2759 | 0.150 |
Why?
|
Divorce | 1 | 2018 | 75 | 0.150 |
Why?
|
Neurotoxicity Syndromes | 1 | 2022 | 301 | 0.150 |
Why?
|
Anxiety | 2 | 2024 | 4573 | 0.150 |
Why?
|
Risk Assessment | 12 | 2020 | 23996 | 0.150 |
Why?
|
Speech Perception | 1 | 2022 | 509 | 0.140 |
Why?
|
Fatigue | 1 | 2024 | 1552 | 0.140 |
Why?
|
Diet | 1 | 2015 | 8075 | 0.140 |
Why?
|
Risk Factors | 22 | 2024 | 74213 | 0.140 |
Why?
|
Organizational Case Studies | 1 | 2017 | 301 | 0.140 |
Why?
|
Radiation Injuries | 2 | 2014 | 1189 | 0.130 |
Why?
|
Magnetic Resonance Spectroscopy | 2 | 2023 | 3769 | 0.130 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2018 | 1784 | 0.130 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2022 | 710 | 0.130 |
Why?
|
Pancreatic Neoplasms | 2 | 2023 | 5368 | 0.130 |
Why?
|
Treatment Outcome | 19 | 2017 | 64685 | 0.130 |
Why?
|
Aged, 80 and over | 22 | 2019 | 58984 | 0.130 |
Why?
|
Combined Modality Therapy | 6 | 2019 | 8527 | 0.120 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2021 | 801 | 0.120 |
Why?
|
Disease-Free Survival | 5 | 2017 | 6815 | 0.120 |
Why?
|
Immunohistochemistry | 5 | 2015 | 11076 | 0.120 |
Why?
|
United States | 26 | 2019 | 72340 | 0.120 |
Why?
|
Smad4 Protein | 1 | 2015 | 191 | 0.120 |
Why?
|
Vasectomy | 1 | 2014 | 51 | 0.120 |
Why?
|
Prognosis | 12 | 2024 | 29629 | 0.110 |
Why?
|
Time Factors | 11 | 2018 | 39969 | 0.110 |
Why?
|
Paraffin Embedding | 1 | 2015 | 302 | 0.110 |
Why?
|
Tissue Fixation | 1 | 2015 | 241 | 0.110 |
Why?
|
Osteopontin | 1 | 2015 | 301 | 0.110 |
Why?
|
Formaldehyde | 1 | 2015 | 358 | 0.110 |
Why?
|
Cyclin D1 | 1 | 2015 | 451 | 0.110 |
Why?
|
Gene Expression Profiling | 4 | 2017 | 9420 | 0.110 |
Why?
|
Depression | 2 | 2024 | 8126 | 0.110 |
Why?
|
Neoplasm Recurrence, Local | 7 | 2016 | 9280 | 0.100 |
Why?
|
Anus Neoplasms | 1 | 2016 | 329 | 0.100 |
Why?
|
Socioeconomic Factors | 6 | 2017 | 7828 | 0.100 |
Why?
|
Nephrectomy | 1 | 2018 | 937 | 0.100 |
Why?
|
Follow-Up Studies | 15 | 2019 | 39106 | 0.100 |
Why?
|
Telephone | 1 | 2016 | 627 | 0.100 |
Why?
|
Rectum | 2 | 2014 | 892 | 0.100 |
Why?
|
Health Status Disparities | 2 | 2014 | 1853 | 0.100 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 899 | 0.100 |
Why?
|
Medically Uninsured | 2 | 2016 | 836 | 0.100 |
Why?
|
Urology | 1 | 2017 | 400 | 0.100 |
Why?
|
Superoxide Dismutase | 1 | 2015 | 594 | 0.100 |
Why?
|
Seminoma | 1 | 2013 | 134 | 0.100 |
Why?
|
Organs at Risk | 1 | 2014 | 359 | 0.100 |
Why?
|
Stromal Cells | 1 | 2017 | 1330 | 0.100 |
Why?
|
Prospective Studies | 8 | 2024 | 54423 | 0.100 |
Why?
|
Survival Rate | 7 | 2016 | 12723 | 0.100 |
Why?
|
Income | 3 | 2014 | 1877 | 0.090 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2014 | 410 | 0.090 |
Why?
|
Survival Analysis | 6 | 2018 | 10090 | 0.090 |
Why?
|
Community Health Services | 1 | 2016 | 656 | 0.090 |
Why?
|
Endoribonucleases | 1 | 2013 | 228 | 0.090 |
Why?
|
Radiotherapy, Conformal | 1 | 2014 | 548 | 0.090 |
Why?
|
Receptor, IGF Type 1 | 1 | 2013 | 380 | 0.090 |
Why?
|
User-Computer Interface | 1 | 2017 | 1400 | 0.090 |
Why?
|
Treatment Refusal | 1 | 2014 | 429 | 0.090 |
Why?
|
Cohort Studies | 11 | 2020 | 41495 | 0.090 |
Why?
|
Delphi Technique | 1 | 2014 | 846 | 0.090 |
Why?
|
Geriatric Assessment | 2 | 2017 | 1410 | 0.090 |
Why?
|
Insulin Resistance | 1 | 2024 | 3964 | 0.090 |
Why?
|
Predictive Value of Tests | 6 | 2018 | 15266 | 0.090 |
Why?
|
beta Carotene | 1 | 2011 | 523 | 0.090 |
Why?
|
Medical Informatics | 1 | 2017 | 733 | 0.090 |
Why?
|
Disease Progression | 6 | 2017 | 13510 | 0.090 |
Why?
|
Artificial Intelligence | 1 | 2024 | 2578 | 0.090 |
Why?
|
Retrospective Studies | 17 | 2024 | 80647 | 0.080 |
Why?
|
Gene Fusion | 1 | 2012 | 356 | 0.080 |
Why?
|
Enzyme Activation | 1 | 2015 | 3597 | 0.080 |
Why?
|
Edema | 1 | 2013 | 766 | 0.080 |
Why?
|
Multivariate Analysis | 6 | 2019 | 12059 | 0.080 |
Why?
|
Ambulatory Care | 1 | 2020 | 2775 | 0.080 |
Why?
|
Consensus | 2 | 2019 | 3124 | 0.080 |
Why?
|
Guidelines as Topic | 1 | 2015 | 1386 | 0.080 |
Why?
|
Sexual Behavior | 1 | 2019 | 2180 | 0.080 |
Why?
|
Antidepressive Agents | 1 | 2021 | 2897 | 0.080 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 2014 | 1148 | 0.080 |
Why?
|
Hyperpigmentation | 1 | 2009 | 117 | 0.080 |
Why?
|
Cause of Death | 6 | 2018 | 3683 | 0.070 |
Why?
|
Adult | 20 | 2024 | 221210 | 0.070 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2009 | 882 | 0.070 |
Why?
|
Health Surveys | 1 | 2017 | 4061 | 0.070 |
Why?
|
Serine Endopeptidases | 1 | 2012 | 1023 | 0.070 |
Why?
|
Genetic Association Studies | 2 | 2015 | 2735 | 0.070 |
Why?
|
Cognition | 1 | 2024 | 6992 | 0.070 |
Why?
|
Myocardial Infarction | 3 | 2013 | 11461 | 0.070 |
Why?
|
Propensity Score | 3 | 2021 | 1913 | 0.070 |
Why?
|
Radiotherapy Dosage | 3 | 2023 | 2898 | 0.070 |
Why?
|
Age Factors | 7 | 2018 | 18399 | 0.070 |
Why?
|
Odds Ratio | 5 | 2017 | 9647 | 0.060 |
Why?
|
Insurance Coverage | 2 | 2014 | 1940 | 0.060 |
Why?
|
Diabetes Mellitus | 1 | 2024 | 5841 | 0.060 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2013 | 1609 | 0.060 |
Why?
|
Epithelial Cells | 1 | 2017 | 3677 | 0.060 |
Why?
|
Alopecia | 1 | 2009 | 412 | 0.060 |
Why?
|
Cost of Illness | 1 | 2015 | 1937 | 0.060 |
Why?
|
Vitamins | 1 | 2013 | 1635 | 0.060 |
Why?
|
Regression Analysis | 4 | 2016 | 6345 | 0.060 |
Why?
|
Farnesyltranstransferase | 1 | 2004 | 71 | 0.060 |
Why?
|
Incidence | 7 | 2015 | 21355 | 0.060 |
Why?
|
Weight Gain | 1 | 2014 | 2348 | 0.060 |
Why?
|
Urogenital System | 1 | 2023 | 88 | 0.060 |
Why?
|
Patient Acceptance of Health Care | 1 | 2017 | 3206 | 0.060 |
Why?
|
Antioxidants | 1 | 2011 | 1668 | 0.060 |
Why?
|
Anti-Inflammatory Agents | 1 | 2013 | 1809 | 0.060 |
Why?
|
Transcription, Genetic | 1 | 2017 | 7593 | 0.050 |
Why?
|
Risk | 4 | 2019 | 9610 | 0.050 |
Why?
|
Software | 1 | 2017 | 4434 | 0.050 |
Why?
|
Lymph Nodes | 1 | 2014 | 3465 | 0.050 |
Why?
|
Cost-Benefit Analysis | 1 | 2016 | 5493 | 0.050 |
Why?
|
Overweight | 1 | 2014 | 2417 | 0.050 |
Why?
|
Health Care Costs | 1 | 2016 | 3242 | 0.050 |
Why?
|
Trans-Activators | 1 | 2012 | 2856 | 0.050 |
Why?
|
Radiation Tolerance | 2 | 2016 | 478 | 0.050 |
Why?
|
Drug Therapy, Combination | 1 | 2012 | 6312 | 0.050 |
Why?
|
Insurance, Health | 1 | 2014 | 2499 | 0.050 |
Why?
|
Aspirin | 1 | 2013 | 3133 | 0.050 |
Why?
|
Coronary Artery Bypass | 1 | 2010 | 2188 | 0.050 |
Why?
|
Sensation Disorders | 1 | 2022 | 160 | 0.050 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2016 | 4024 | 0.050 |
Why?
|
Biopsy, Needle | 2 | 2017 | 1626 | 0.050 |
Why?
|
Health Services Accessibility | 1 | 2018 | 5440 | 0.050 |
Why?
|
Carrier Proteins | 1 | 2014 | 4937 | 0.050 |
Why?
|
Fiducial Markers | 1 | 2021 | 132 | 0.040 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 11742 | 0.040 |
Why?
|
Coronary Disease | 1 | 2014 | 5914 | 0.040 |
Why?
|
RNA, Messenger | 1 | 2015 | 12794 | 0.040 |
Why?
|
Confidence Intervals | 2 | 2015 | 2927 | 0.040 |
Why?
|
Electronic Health Records | 1 | 2017 | 4811 | 0.040 |
Why?
|
Physicians | 1 | 2017 | 4591 | 0.040 |
Why?
|
Infusions, Intravenous | 1 | 2004 | 2217 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 3 | 2023 | 36426 | 0.040 |
Why?
|
Quality Improvement | 1 | 2014 | 3802 | 0.040 |
Why?
|
Disease Management | 2 | 2019 | 2508 | 0.040 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 3246 | 0.040 |
Why?
|
Ovarian Neoplasms | 1 | 2015 | 4878 | 0.040 |
Why?
|
Pharmacogenetics | 1 | 2022 | 675 | 0.040 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2017 | 3779 | 0.040 |
Why?
|
Speech | 1 | 2022 | 554 | 0.040 |
Why?
|
Obesity | 2 | 2024 | 12947 | 0.040 |
Why?
|
Organ Size | 2 | 2013 | 2254 | 0.030 |
Why?
|
Heart Failure | 2 | 2011 | 11671 | 0.030 |
Why?
|
Educational Status | 2 | 2014 | 2522 | 0.030 |
Why?
|
Marriage | 1 | 2018 | 351 | 0.030 |
Why?
|
Cryotherapy | 1 | 2017 | 159 | 0.030 |
Why?
|
Stents | 2 | 2023 | 3179 | 0.030 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2017 | 297 | 0.030 |
Why?
|
Data Display | 1 | 2016 | 175 | 0.030 |
Why?
|
Body Composition | 1 | 2024 | 2426 | 0.030 |
Why?
|
Feasibility Studies | 2 | 2017 | 5247 | 0.030 |
Why?
|
Disabled Persons | 1 | 2024 | 1226 | 0.030 |
Why?
|
Trypsin Inhibitor, Kazal Pancreatic | 1 | 2014 | 30 | 0.030 |
Why?
|
Goserelin | 1 | 2014 | 126 | 0.030 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2023 | 1660 | 0.030 |
Why?
|
Delayed Diagnosis | 1 | 2018 | 463 | 0.030 |
Why?
|
Minority Health | 1 | 2014 | 79 | 0.030 |
Why?
|
Diagnosis-Related Groups | 1 | 2015 | 449 | 0.030 |
Why?
|
Survival | 1 | 2013 | 161 | 0.030 |
Why?
|
Community Health Centers | 1 | 2017 | 461 | 0.030 |
Why?
|
Leuprolide | 1 | 2014 | 312 | 0.030 |
Why?
|
Epithelium | 1 | 2017 | 1603 | 0.030 |
Why?
|
Phantoms, Imaging | 1 | 2021 | 2526 | 0.030 |
Why?
|
Tissue Array Analysis | 1 | 2014 | 550 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2004 | 10766 | 0.020 |
Why?
|
Congresses as Topic | 1 | 2017 | 803 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2014 | 15633 | 0.020 |
Why?
|
Signal Transduction | 1 | 2015 | 23447 | 0.020 |
Why?
|
Drug Prescriptions | 1 | 2021 | 1670 | 0.020 |
Why?
|
Demography | 1 | 2016 | 1648 | 0.020 |
Why?
|
Area Under Curve | 1 | 2015 | 1638 | 0.020 |
Why?
|
Urethra | 1 | 2013 | 405 | 0.020 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2015 | 857 | 0.020 |
Why?
|
Neoadjuvant Therapy | 2 | 2013 | 2828 | 0.020 |
Why?
|
Epidemiologic Methods | 1 | 2015 | 1336 | 0.020 |
Why?
|
Lymphoma, Mantle-Cell | 1 | 2013 | 237 | 0.020 |
Why?
|
Kidney Diseases | 1 | 2021 | 2091 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2020 | 2917 | 0.020 |
Why?
|
Waist Circumference | 1 | 2013 | 935 | 0.020 |
Why?
|
Iodine Radioisotopes | 1 | 2013 | 1031 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2017 | 8554 | 0.020 |
Why?
|
Phenotype | 2 | 2018 | 16592 | 0.020 |
Why?
|
Young Adult | 4 | 2021 | 59260 | 0.020 |
Why?
|
Self Report | 1 | 2021 | 3725 | 0.020 |
Why?
|
History, 21st Century | 1 | 2015 | 1567 | 0.020 |
Why?
|
Morbidity | 1 | 2015 | 1752 | 0.020 |
Why?
|
Muscle, Skeletal | 1 | 2024 | 4948 | 0.020 |
Why?
|
Sex Distribution | 1 | 2014 | 2280 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2017 | 3514 | 0.020 |
Why?
|
Female | 9 | 2016 | 392705 | 0.020 |
Why?
|
Lymphoma, Follicular | 1 | 2013 | 457 | 0.020 |
Why?
|
Liver | 1 | 2024 | 7528 | 0.020 |
Why?
|
Evolution, Molecular | 1 | 2016 | 1886 | 0.020 |
Why?
|
Radiometry | 1 | 2013 | 813 | 0.020 |
Why?
|
Mortality | 1 | 2019 | 2902 | 0.020 |
Why?
|
Angioplasty | 1 | 2010 | 355 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2004 | 16990 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2015 | 10212 | 0.020 |
Why?
|
History, 20th Century | 1 | 2015 | 2767 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2015 | 2915 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2015 | 3597 | 0.020 |
Why?
|
Gene Rearrangement | 1 | 2012 | 1125 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2021 | 3530 | 0.020 |
Why?
|
Bone and Bones | 1 | 2017 | 2568 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2017 | 6484 | 0.020 |
Why?
|
Physical Examination | 1 | 2013 | 1255 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2017 | 4915 | 0.020 |
Why?
|
Treatment Failure | 1 | 2013 | 2643 | 0.020 |
Why?
|
Germ-Line Mutation | 1 | 2015 | 1858 | 0.020 |
Why?
|
Health Services Needs and Demand | 1 | 2014 | 1403 | 0.020 |
Why?
|
Body Mass Index | 2 | 2014 | 12953 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 2 | 2018 | 17904 | 0.020 |
Why?
|
Linear Models | 1 | 2015 | 5872 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2014 | 6228 | 0.020 |
Why?
|
Guideline Adherence | 1 | 2015 | 2220 | 0.020 |
Why?
|
Qualitative Research | 1 | 2016 | 3025 | 0.020 |
Why?
|
Up-Regulation | 1 | 2013 | 4125 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2015 | 15936 | 0.010 |
Why?
|
Boston | 1 | 2017 | 9327 | 0.010 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2014 | 1188 | 0.010 |
Why?
|
Mutation | 2 | 2020 | 30053 | 0.010 |
Why?
|
Biopsy | 1 | 2015 | 6766 | 0.010 |
Why?
|
Genome, Human | 1 | 2016 | 4425 | 0.010 |
Why?
|
Social Support | 1 | 2013 | 2172 | 0.010 |
Why?
|
Body Weight | 1 | 2014 | 4618 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2013 | 3208 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2022 | 12690 | 0.010 |
Why?
|
Poverty | 1 | 2014 | 2697 | 0.010 |
Why?
|
Massachusetts | 1 | 2015 | 8833 | 0.010 |
Why?
|
Radiography | 1 | 2013 | 6965 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2016 | 5305 | 0.010 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2013 | 1640 | 0.010 |
Why?
|
Health Policy | 1 | 2013 | 2684 | 0.010 |
Why?
|
C-Reactive Protein | 1 | 2013 | 3826 | 0.010 |
Why?
|
Algorithms | 1 | 2021 | 14033 | 0.010 |
Why?
|
Sex Factors | 1 | 2014 | 10554 | 0.010 |
Why?
|
Registries | 1 | 2016 | 8225 | 0.010 |
Why?
|
Animals | 1 | 2011 | 168475 | 0.010 |
Why?
|
Adolescent | 2 | 2021 | 88326 | 0.010 |
Why?
|
Comorbidity | 1 | 2013 | 10508 | 0.010 |
Why?
|
Genotype | 1 | 2013 | 12990 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2011 | 12341 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2013 | 7391 | 0.010 |
Why?
|
Inflammation | 1 | 2013 | 10774 | 0.010 |
Why?
|
Child | 1 | 2021 | 80158 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 2013 | 15502 | 0.000 |
Why?
|